CD177, a specific marker of neutrophil activation, is a hallmark of COVID-19 severity and death

Yves Lévy, Aurélie Wiedemann, Boris P. Hejblum, Mélany Durand, Cécile Lefebvre, Mathieu Surénaud, Christine Lacabaratz, Matthieu Perreau, Emile Foucat, Marie Déchenaud, Pascaline Tisserand, Fabiola Blengio, Benjamin Hivert, Marine Gautier‐Isola, Minerva Cervantes-Gonzalez, Delphine Bachelet, Cédric Laouenan, Lila Bouadma, Jean‐François Timsit, Yazdan Yazdanpanah, Giuseppe Pantaleo, Hakim Hocini, Rodolphe Thiébaut, the French Covid cohort study groupmedRxiv 2020 · DOI

Abstract

SARS-CoV-2 infection exhibits extreme clinical variability, ranging from asymptomatic cases to fatal multi-organ failure. Identifying high-risk patients during the early stages of hospitalization remains a significant clinical challenge. In this study, we analyzed 52 cell populations, 71 analytes, and whole-blood RNA-seq gene expression from patients in the French COVID cohort. Our multi-omics approach identified severe abnormalities in 27 cell populations and the elevation of 42 inflammatory components in COVID-19 patients. Unsupervised analysis highlighted neutrophil activation as a dominant feature of severe disease, specifically identifying CD177—a marker of neutrophil activation and transmigration—as the most highly differentially expressed gene. CD177 protein levels in serum were significantly higher in ICU patients compared to non-ICU patients across both French and Swiss cohorts. Furthermore, longitudinal monitoring revealed that sustained high levels of CD177 distinguish patients with the worst prognosis from those who recover, establishing CD177 as a robust prognostic marker for routine clinical care.

Introduction

The clinical progression of COVID-19 is often unpredictable. Many patients experience a "critical window" approximately one week after symptom onset, during which they either begin to recover or rapidly deteriorate into respiratory failure. While systemic inflammation and "cytokine storms" are well-documented, there is an urgent need for specific, measurable biomarkers that can predict these trajectories. This research sought to move beyond broad inflammatory descriptions to identify the specific molecular drivers of severe COVID-19 using a systems immunology approach.

Methodology and Data Integration

To capture the complexity of the host immune response, the researchers utilized a multi-omics framework on a discovery cohort of 61 severe patients from the French COVID cohort. The methodology integrated three distinct layers of biological data:

  1. Cellular Phenotyping: Flow cytometry was used to analyze 52 different immune cell populations.
  2. Soluble Proteomics: Multiplex assays measured 71 serum analytes, including cytokines and chemokines.
  3. Transcriptomics: Whole-blood RNA-seq identified gene expression patterns associated with disease progression.

These datasets were integrated using Multi-Omics Factor Analysis (MOFA), a statistical tool that identifies common factors across disparate data types. The findings were subsequently validated in an expanded French cohort (n=115) and an independent Swiss confirmatory cohort (n=88), comparing results against healthy donors (HDs).

The Prominence of Neutrophil Activation

The integrated analysis revealed that neutrophil activation is the most significant driver of the immune signature in severe COVID-19. While much of the early pandemic research focused on T-cell exhaustion and lymphopenia, these data suggest that the innate response—specifically the over-activation of neutrophils—is a primary hallmark of severity.

Among thousands of genes, CD177 emerged as the most highly differentially expressed. CD177 is a glycosylphosphatidylinositol (GPI)-anchored protein expressed on the surface of neutrophils; it plays a critical role in their adhesion to the endothelium and subsequent migration into tissues. The study found a robust correlation (0.88) between CD177 gene expression and the concentration of CD177 protein in the serum, suggesting that a standard protein-based blood test could effectively mirror the underlying genetic activation.

Clinical Results and Prognostic Value

The study demonstrated that CD177 levels are directly tied to clinical outcomes:

  • Severity Discrimination: CD177 protein levels were significantly higher in patients requiring intensive care (ICU) than in those managed in conventional wards ($P < 0.001$). This association held true even after adjusting for age, sex, and comorbidities (adjusted odds ratio of 1.14 per unit increase).
  • Temporal Correlation: CD177 levels correlated with the time from symptom onset, peaking during the window when clinical worsening typically occurs.
  • Mortality Prediction: Perhaps most importantly, longitudinal data showed that patients who eventually died maintained high, stable levels of serum CD177. In contrast, patients who recovered showed a steady decline in CD177 levels over time ($P = 0.01$). This suggests that the failure to downregulate neutrophil activation is a lethal feature of the disease.

Discussion and Implications

These findings position CD177 as more than just a marker of inflammation; it is a specific indicator of the neutrophil-mediated tissue invasion that characterizes severe COVID-19. The high correlation between transcriptomic data and serum protein levels makes CD177 a prime candidate for translation into routine clinical assays, such as ELISA, which are faster and more cost-effective than RNA sequencing.

While the study establishes CD177 as a powerful prognostic tool, further research is required to determine if CD177 is a functional driver of lung injury or a secondary marker of the systemic neutrophil response. Regardless, the ability to identify patients with sustained CD177 elevation early in their hospital stay could allow clinicians to prioritize high-risk individuals for intensive monitoring or emerging therapies targeting neutrophil-led inflammation.

Summary updated

Abstract

Abstract COVID-19 SARS-CoV-2 infection exhibits wide inter-individual clinical variability, from silent infection to severe disease and death. The identification of high-risk patients is a continuing challenge in routine care. We aimed to identify factors that influence clinical worsening. We analyzed 52 cell populations, 71 analytes, and RNA-seq gene expression in the blood of severe patients from the French COVID cohort upon hospitalization (n = 61). COVID-19 patients showed severe abnormalities of 27 cell populations relative to healthy donors (HDs). Forty-two cytokines, neutrophil chemo-attractants, and inflammatory components were elevated in COVID-19 patients. Supervised gene expression analyses showed differential expression of genes for neutrophil activation, interferon signaling, T- and B-cell receptors, EIF2 signaling, and ICOS-ICOSL pathways in COVID-19 patients. Unsupervised analysis confirmed the prominent role of neutrophil activation, with a high abundance of CD177, a specific neutrophil activation marker. CD177 was the most highly differentially-expressed gene contributing to the clustering of severe patients and its abundance correlated with CD177 protein serum levels. CD177 levels were higher in COVID-19 patients from both the French and “confirmatory” Swiss cohort (n = 203) than in HDs (P&lt; 0.01) and in ICU than non-ICU patients (P&lt; 0.001), correlating with the time to symptoms onset (P = 0.002). Longitudinal measurements showed sustained levels of serum CD177 to discriminate between patients with the worst prognosis, leading to death, and those who recovered (P = 0.01). These results highlight neutrophil activation as a hallmark of severe disease and CD177 assessment as a reliable prognostic marker for routine care.
BibTeX
@misc{levy2020cd,
  author = {Yves Lévy and Aurélie Wiedemann and Boris P. Hejblum and Mélany Durand and Cécile Lefebvre and Mathieu Surénaud and Christine Lacabaratz and Matthieu Perreau and Emile Foucat and Marie Déchenaud and Pascaline Tisserand and Fabiola Blengio and Benjamin Hivert and Marine Gautier‐Isola and Minerva Cervantes-Gonzalez and Delphine Bachelet and Cédric Laouenan and Lila Bouadma and Jean‐François Timsit and Yazdan Yazdanpanah and Giuseppe Pantaleo and Hakim Hocini and Rodolphe Thiébaut and the French COVID cohort study group},
  title = {{CD177, a specific marker of neutrophil activation, is a hallmark of COVID-19 severity and death}},
  year = {2020},
  doi = {10.1101/2020.12.12.20246934},
  howpublished = {medRxiv},
}
Figure